Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions

被引：0
|
作者：
Claire E. P. Smith
Paul K. Marcom
Zahi Mitri
Naomi Y. Ko
机构：
[1] Boston University School of Medicine,Duke Cancer Center
[2] Boston Medical Center,undefined
[3] Duke University Hospital,undefined
[4] Oregon Health and Science University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词：
Breast Cancer; HER2; Trastuzumab; Neoplasm metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：215 / 220
页数：5
相关论文
共 50 条
  • [21] Treatment of HER2-Positive Metastatic Breast Cancer
    van Ramshorst, Mette S.
    Sonke, Gabe S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1964 - 1964
  • [22] Long-term responders to trastuzumab among patients with HER2-positive metastatic breast cancer
    Barriere, J.
    Mari, V.
    Follana, P.
    Largillier, R.
    Chamorey, E.
    Lescaut, W.
    Flipo, B.
    Ettore, F.
    Raoust, I.
    Peyrottes, I.
    Figl, A.
    Marcy, M.
    Ihrai, T.
    Courdi, A.
    Ferrero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
    Yardley, D. A.
    Tripathy, D.
    Brufsky, A. M.
    Rugo, H. S.
    Kaufman, P. A.
    Mayer, M.
    Magidson, J.
    Yoo, B.
    Quah, C.
    Yood, M. Ulcickas
    BRITISH JOURNAL OF CANCER, 2014, 110 (11) : 2756 - 2764
  • [24] Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
    Omarini, Claudia
    Bettelli, Stefania
    Caprera, Cecilia
    Manfredini, Samantha
    Caggia, Federica
    Guaitoli, Giorgia
    Moscetti, Luca
    Toss, Angela
    Cortesi, Laura
    Kaleci, Shaniko
    Maiorana, Antonino
    Cascinu, Stefano
    Conte, Pier Franco
    Piacentini, Federico
    CANCER BIOLOGY & THERAPY, 2018, 19 (10) : 879 - 886
  • [25] Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
    D A Yardley
    D Tripathy
    A M Brufsky
    H S Rugo
    P A Kaufman
    M Mayer
    J Magidson
    B Yoo
    C Quah
    M Ulcickas Yood
    British Journal of Cancer, 2014, 110 : 2756 - 2764
  • [26] Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
    Battisti, Nicolo Matteo Luca
    Tong, Daniel
    Ring, Alistair
    Smith, Ian
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (02) : 401 - 408
  • [27] Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience
    Nicolò Matteo Luca Battisti
    Daniel Tong
    Alistair Ring
    Ian Smith
    Breast Cancer Research and Treatment, 2019, 178 : 401 - 408
  • [28] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [29] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Mueller, Volkmar
    Clemens, Michael
    Jassem, Jacek
    Al-Sakaff, Nedal
    Auclair, Petra
    Nuesch, Eveline
    Holloway, Debbie
    Shing, Mona
    Bang, Yung-Jue
    BMC CANCER, 2018, 18
  • [30] Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
    Volkmar Müller
    Michael Clemens
    Jacek Jassem
    Nedal Al-Sakaff
    Petra Auclair
    Eveline Nüesch
    Debbie Holloway
    Mona Shing
    Yung-Jue Bang
    BMC Cancer, 18
12345